vs

Side-by-side financial comparison of Opera Ltd (OPRA) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $142.7M, roughly 1.6× Opera Ltd). Organogenesis Holdings Inc. runs the higher net margin — 19.4% vs 12.8%, a 6.6% gap on every dollar of revenue.

Opera is a multinational technology corporation headquartered in Oslo, Norway, with additional offices in Europe, China, and Africa. Opera offers a range of products and services that include PC and mobile web browsers, GameMaker and gaming portals, the Opera News content recommendation products, the Opera Ads platform, and a number of Web3 and e-commerce products and services. The company's total user base is 296 million monthly active users.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

OPRA vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.6× larger
ORGO
$225.6M
$142.7M
OPRA
Higher net margin
ORGO
ORGO
6.6% more per $
ORGO
19.4%
12.8%
OPRA

Income Statement — Q1 FY2025 vs Q4 FY2025

Metric
OPRA
OPRA
ORGO
ORGO
Revenue
$142.7M
$225.6M
Net Profit
$18.3M
$43.7M
Gross Margin
Operating Margin
14.8%
28.1%
Net Margin
12.8%
19.4%
Revenue YoY
78.1%
Net Profit YoY
469.5%
EPS (diluted)
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OPRA
OPRA
ORGO
ORGO
Q4 25
$225.6M
Q3 25
$150.9M
Q2 25
$101.0M
Q1 25
$142.7M
$86.7M
Q4 24
$126.7M
Q3 24
$115.2M
Q2 24
$211.6M
$130.2M
Q1 24
$110.0M
Net Profit
OPRA
OPRA
ORGO
ORGO
Q4 25
$43.7M
Q3 25
$21.6M
Q2 25
$-9.4M
Q1 25
$18.3M
$-18.8M
Q4 24
$7.7M
Q3 24
$12.3M
Q2 24
$34.1M
$-17.0M
Q1 24
$-2.1M
Gross Margin
OPRA
OPRA
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Q1 24
73.9%
Operating Margin
OPRA
OPRA
ORGO
ORGO
Q4 25
28.1%
Q3 25
13.7%
Q2 25
-12.5%
Q1 25
14.8%
-30.9%
Q4 24
8.1%
Q3 24
5.4%
Q2 24
19.6%
-10.7%
Q1 24
-3.5%
Net Margin
OPRA
OPRA
ORGO
ORGO
Q4 25
19.4%
Q3 25
14.3%
Q2 25
-9.3%
Q1 25
12.8%
-21.7%
Q4 24
6.1%
Q3 24
10.7%
Q2 24
16.1%
-13.1%
Q1 24
-1.9%
EPS (diluted)
OPRA
OPRA
ORGO
ORGO
Q4 25
$0.31
Q3 25
$0.11
Q2 25
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$-0.13
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OPRA
OPRA
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$300.1M
Total Assets
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OPRA
OPRA
ORGO
ORGO
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Q1 24
$88.6M
Total Debt
OPRA
OPRA
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
OPRA
OPRA
ORGO
ORGO
Q4 25
$300.1M
Q3 25
$255.1M
Q2 25
$233.2M
Q1 25
$242.9M
Q4 24
$262.9M
Q3 24
$278.5M
Q2 24
$263.5M
Q1 24
$278.0M
Total Assets
OPRA
OPRA
ORGO
ORGO
Q4 25
$598.7M
Q3 25
$509.8M
Q2 25
$461.1M
Q1 25
$467.4M
Q4 24
$497.9M
Q3 24
$446.3M
Q2 24
$443.2M
Q1 24
$458.5M
Debt / Equity
OPRA
OPRA
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OPRA
OPRA
ORGO
ORGO
Operating Cash FlowLast quarter
$39.4M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OPRA
OPRA
ORGO
ORGO
Q4 25
$39.4M
Q3 25
$3.1M
Q2 25
$-32.9M
Q1 25
$-19.9M
Q4 24
$10.9M
Q3 24
$8.7M
Q2 24
$4.7M
Q1 24
$-10.2M
Free Cash Flow
OPRA
OPRA
ORGO
ORGO
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
Q1 24
$-12.4M
FCF Margin
OPRA
OPRA
ORGO
ORGO
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Q1 24
-11.3%
Capex Intensity
OPRA
OPRA
ORGO
ORGO
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Q1 24
2.0%
Cash Conversion
OPRA
OPRA
ORGO
ORGO
Q4 25
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons